About CVPath

Press Release

Recent News:

Allow us to wish you a fine new year and take this opportunity to advise you of significant developments at CVPath Institute.


Beginning in December 2016, we will begin to offer micro-computerized tomography (CT) services in-house.  We have acquired a state-of-the-art Nikon XTH 225 ST for high-speed computerized tomography and real-time X ray visualization.  This service will be available to all clients for all tissues and we anticipate that it will lower our turnaround time for specimens undergoing CT as well as histological analysis. This will eliminate the need to send tissues away for CT analysis.  Micro CT will also be offered as a stand-alone service.


We have also acquired a state-of-the-art Zeiss 880 high resolution confocal microscope for cellular imaging. This is allowing us to understand in ways we never have before the function of regenerated endothelial layer that covers stents and to investigate other areas of cardiovascular biology pertinent to vascular disease and its treatment. Below we have provided an example where we have stained a rabbit iliac implanted with a drug-eluting stent with antibodies against the endothelial junctional protein VE-cadherin (shown in red) and the beta-catenin which stabilizes VE-cadherin p120 (shown in green).  You can see that the two proteins co-localize at the borders of endothelial cells. A side branch is shown in the center of the picture.



Of the many publications written by the CVPath team this past year we would like to point your attention to a review in Nature Reviews Cardiology Pathophysiology of native, vein graft, and in-stent atherosclerosis highlighting pathological differences in these three vascular disease entities. In addition, Drs. Finn and Virmani wrote 2 editorials in the Lancet this year on important clinical trials in the field of interventional cardiology. The first pertained to a meta-analysis of 6 clinical trials published in November comparing outcomes using the Abbott bioabsorable vascular scaffold (BVS, Absorb) versus the permanent polymer everolimus eluting stent. The editorial highlights concerns regarding increase rates of early stent thrombosis seen in patients receiving BVS but also the potential benefits of such a device. The second editorial pertains to a clinical trial comparing outcomes in bioabsorable polymer drug eluting stents versus permanent polymer drug-eluting stents. The editorial puts forth our opinion on the potential benefits of a bioabsorable polymer metallic stents and was published in October 2016.